Skip to main content
Elsevier
View Cart

Cannabis, Cannabinoids, and Endocannabinoids

  • 1st Edition - June 24, 2023
  • Latest edition
  • Editors: Colin R. Martin, Vinood B. Patel, Victor R. Preedy
  • Language: English

Cannabis, Cannabinoids, and Endocannabinoids offers a comprehensive reference on natural and synthetic cannabinoids, providing coverage on both adverse and non-adverse effects,… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

Cannabis, Cannabinoids, and Endocannabinoids offers a comprehensive reference on natural and synthetic cannabinoids, providing coverage on both adverse and non-adverse effects, including reactivity to pain, changes in behavior and neuroactivity. This volume updates on research on the effects of these compounds in brain function and neurological dysfunction, offering readers a comprehensive reference on medical usage and the symptom relief provided by these compounds. With coverage of neurological diseases like Alzheimer’s and Parkinson’s, and a wide range of other afflictions, including depression, anxiety, nausea and cancer, this broad coverage expounds on the physiological, psychological and pharmacological effects of these compounds.

Unique case reports are also provided, creating a platform for research on the use of these compounds in improving patient care, brain function and neurological dysfunction. As the endocannabinoid system has been implicated in various neurological conditions, this book is a welcomed resource on the topics presented.

Key features

  • Summarizes cannabis and cannabinoid research in relation to neurological function
  • Covers the neuroactivity of multiple cannabis compounds beyond tetrahydrocannabinol
  • Includes conditions like depression, anxiety, Parkinson’s, psychosis and epilepsy
  • Discusses concepts in the context of brain structure and brain development, including functional connectivity
  • Summarizes the medicinal usage of cannabis and cannabinoids in a variety of conditions
  • Examines symptom control of conditions, including depression, anxiety and sleep
  • Discusses cannabis usage in Alzheimer’s, Parkinson’s, Multiple Sclerosis, and cancer

Readership

Researchers in neuroscience and the biomedical sciences; behavioral neuroscientists

Table of contents

Cannabis Use, Neurobiology, Psychology, and TreatmentI. Setting the scene and introductory chapters1. Metabolomics of the cannabis plantMickel Hiebert-Giesbrecht, Claudia Torres-Calzada and David Scott Wishart2. The roots of Cannabis sativa: chemical and pharmacological profileL A. Rolim3. Cannabis related compounds in beverages and foodIlaria Di Marco Pisciottano4. The impact of prenatal cannabis exposure: an overviewNatalia Kleinhans5. Cannabinoid Genotoxicity and Congenital Anomalies: A Convergent Synthesis of European and USA DatasetsAlbert Stuart Reece and Gary K. Hulse6. Cannabis Genotoxicity and Cancer Incidence: A Highly Concordant Synthesis of European and USA DatasetsAlbert Stuart Reece and Gary K. Hulse7. Cannabis, Cognitive impairment and Car Crash risk U.W. Preuss

II. Cannabis usage

8. Recreational cannabis use: a French perspective of adverse effectsEmilie Bouquet, Emilie Jouanjus and Maryse Lapeyre-Mestre9. Acute and chronic impact of cannabis on human cognitionJustin Matheson and Bernard Le Foll10. Polydrug users, use of cannabidiol (CBD) and abuse potential/Polydrug users, use of cannabinoids and abuse potentialKerri Alexandra Schoedel11. Cannabis stigmas: a narrative of featuresMatt Reid12. Alterations of THC and CBD ratios and impact on cognitionErica Zamberletti13. When cannabis is used for medicinal purposes: a focus on back painR. L. Price III

III. Pharmacological and Physiological Aspects

14. Cannabis, cannabinoids and receptor responsesYi Yang, Roya Derwish and Lakshmi P. Kotra15. Cannabidiol (CBD): abuse potential and withdrawalKenneth W. Sommerville and Beatrice Setnik16. 4,5- Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal applications Malliga R. Iyer

IV. Neurobiology of cannabis

17. Neurobiology of cannabisRohit Goyal and Deepak Kumar18. The kynurenine pathway, neurobiology and cannabis misuse: a new narrativeNuria Morales-Puerto and Esther O'Shea19. Central nervous system cancers and use of cannabis and related products: an updated narrativeJ. Eduardo Rodriguez Almaraz and Nicholas Butowski20. Chronic cannabis users: links with glutamate and resting state connectivityS.D. Newman21. Brain metabolic responses to cannabis use in people with multiple sclerosis: Insights from [18F]-FDG positron emission tomography and functional MRIThorsten Rudroff22. Genetic Variation and Acute Responses to Cannabis Bernard Le Foll, Zoe Bourgault and Justin Matheson23. Cell Signaling of the CB1 Cannabinoid Receptor via beta-arrestins, Cannabinoid Receptor Interacting Protein (CRIP1a) and other regulatory proteinsAllyn C. Howlett24. Cannabis and impact on memory: from in utero to adultsJennifer Willford, Meaghan Hazelet, Mohamad Khalaifa, Natacha DeGenna and Gale A. Richardson25. Central CB1 receptors and age-related changes: investigating the effects of DELTA-9-tetrahydrocannabinolBrett C. Ginsburg and Hanana AlTfaili26. Alcohol, cannabis and visual memoryConcepcion Vinader-Caerols

V. Neurobiology of cannabinoids

27. The role of Delta-FosB in the plasticity of the cannabinoid systemArturo Venebra-Munoz and Sara Mejía-Chávez28. Functional profile of synthetic cannabinoid receptor agonists: exploring cannabinoid and non-cannabinoid targets Shivani Sachdev, Marina Santiago and Chris Bladen29. Linking the G protein-coupled orphan receptor GPR55 to the cannabinoid receptors (CB1 and CB2): a new narrativePaula Morales, Raquel Guerrero-Alba and B.A. Marichal-Cancino30. Proteomic analysis of cannabinoids in human oligodendrocytesValéria Almeida31. Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic systemRafael Rodriguez32. Cannabidiol (The major non-psychotropic cannabinoid in the cannabis plant) and the PI3K/Akt pathway in the CNSNadja Schroder33. Effects of cannabidiol and other phytocannabinoids on ion channelsMurat Oz, Keun-Hang Susan Yang, Mohamed Mahgoub, Georg Petroianu and Dietrich Lorke34. Cannabis, neurodevelopment and the "two-hit hypothesis"Elisa Guma, Lani Cupo and Mallar Chakravarty

VI. New and synthetic cannabinoids

35. Impact of tetrahydrocannabinol (THC ) and synthetic "spice"cannabinoids on nicotine use and abuseChristie Dawn Fowler and Angeline Dukes36. Synthetic cannabinoids: how do they compare to DELTA9-tetrahydrocannabinol: neurological effects and beyondChris S. Breivogel

VII. Biomarkers, analysis and screening

37. The DSM-5 criteria of cannabis use disorder: methods and applicationsMahadev Sen, Siddharth Sarkar and Yesh Singh38. Cannabis and clinical high risk for psychosis: monitoring and smartphonesJean Addington

VIII. Impact on non-neurological systems39. The impact of cannabis and cannabinoids on the skinJane M. Grant-Kels40. Cannabis consumption in reproduction and teratogenicitySusana Sa and B.M. Fonseca41. Cannabis compounds and putative cytotoxicity: profile of cancer cellsHadar Peeri and Hinanit Koltai

IX. Treatments, strategies and resources

42. Motivational Interviewing for Cannabis Use Disorders: a narrative review from research to practiceHugo López-Pelayo, Maria Teresa Pons-Cabrera, Clara Oliveras Salvà and Pablo Rodrigo Guzmán Cortez43. An Overview of Current Pharmacologic Interventions for Management of Cannabis Withdrawal and the Evidence for Their UseDavid Wolinsky44. Managing cannabinoid hyperemesis syndrome in paediatrics: A new narrative reviewJustin P. Reinert45. Gabapentinoids for the Treatment of Cannabis Use Disorder: A Focus on Human Laboratory ResearchJoshua A. Lile46. Treating psychosis in users of synthetic cannabinoidsT. Klimenko and Svetlana Shakhova

X. Resources

47. Cannabis and Web based ResourcesRajkumar Rajendram

　

Medicinal Usage of Cannabis and Cannabinoids

I. Setting the scene and introductory chapters1. How medical cannabis may influence the future of medicineMartha ROSENTHAL2. Medical cannabis and cannabinoids: how best to extract components from plant material Daniela De Vita, Valentina Noemi Madia and Roberta Costi3. Medicinal usage of cannabis and its impact on mental health among cancer patients and survivors Nicolas Hernandez Ortega, Ye Chen, Jessica Y. Islam, Diane Rodriguez, Marlene Camacho-Rivera and D.C. Vidot4. Cannabis sativa as a traditional phytomedicine: a new narrative covering different countries M.N. Ahmed, Tridib Paul, Md. Nur Kabidul Azam, Rownak Jahan and Mohammed Rahmatullah5. Medical use of cannabis in the middle east Bader Hamza Shirah, Mohammed Ahmed and Ruba Saleh6. What medicinal cannabis is used for: a focus on Canada Dean T. Eurich, Cerina Lee and Jason Dyck7. New York perspectives of medical cannabis laboratory analysisLingyun Li, Stacey Chmura, Christopher Judd and Bryan C. Duffy8. Epigenetic regulations on the quality of clonal cannabis plants: secondary metabolites and profiles Mohsen Hesami and Max Jones9. Aberrant use of medicinal cannabis: theoretical and empirical considerations Daniel Feingold10. Profile of older users of medical cannabis and cannabinoidsJoshua Brown11. Use of cannabidiol oil by caregivers: a focus on Alzheimer's diseaseMagdalena Leszko12. Medicinal use of cannabis: adverse events as a balanced perspectiveGiada Crescioli, Valentina Maggini, Fabio Firenzuoli, Alfredo Vannacci and Niccolo Lombardi

II. Physiological aspects and metabolic aspects13. Physiopathology and use of cannabinoids for fibrotic diseases Carmen del Rio and E. Munoz14. Cannabinoids in inflammation and atherosclerosis Leonor Thomson, Edward Moreira-Bahnson and Bruno Musetti15. Targeting the CB(2) receptors and other endocannabinoid elements to delay disease progression in cardiovascular diseasesShreesh Ojha16. BMI in cannabis users: regulation, mechanisms and public health impact Thomas Clark

III. Neurological, psychological and behavioural aspects17. Neuroprotection by cannabis related products, cannabidiol and cannabigerol, and associated mechanisms of actionCarolina Echeverry Sr., Jimena Fagetti, Miguel Reyes-Parada and Cecilia Scorza18. Cannabis terpenes as neuroprotective agents: a focus on alpha-bisabololJohn Staton Laws, Srijan Shrestha and Scott D. Smid19. Cannabidiol in medicinal usage of stress: modelling investigations into cocaineM. Julia García-Fuster and Olga Valverde20. Medicinal cannabis and neurocognition impairmentCaroline MacCallum, April Christiansen, Lindsay Lo, Carly Pistawka, Michael Boivin and Melissa Snider-Adler21. Genetic models of audiogenic seizures: what they are and how cannabinoids and Cannabis-derived compounds can be used to alleviate their symptoms - an updated narrativeNorberto Garcia-Cairasco22. Addressing the validity of cannabinoid therapy as an option for the treatment of substance use disorderRose Chesworth, Erin McLemon and Tim Karl

IV. Pharmacological and cellular aspects23. Cannabidiolic acid (CBDA), features and profiles: anti-hyperalgesic effects G. Singh, Katja Linher-Melville and Raphael Mechoulam24. Cannabis-drug interactions: implications for medicinal cannabis use Fran Gengo, Anna Mattle and Christopher Ralyea25. Cannabinoid receptor subtype 2 (CB2R): features and targets for medical applications Marialessandra Contino, Carmen Abate, Nicola Antonio Colabufo, Francesco Leonetti and Angela Stefanachi26. Medical use of cannabidiol and impact on cancer cell viability `Kent E. Chair and Wesley Raup-Konsavage27. Anti-inflammatory and antioxidant and immunomodulatory effects of phytocannabinoid ‑caryophyllene: A mechanistic overviewVafa Baradaran Rahimi, Arghavan Memarzia and Prof. Vahid Reza Askari

V. Symptom Control and Medicinal Uses28. Cancer patients and providers: Attitudes and beliefs of cannabis and cannabinoids use as a treatment Kimberson Tanco29. CBD (cannabidiol) use in breast cancer chemotherapyAna I. Torres-Suarez, Ana Isabel Fraguas-Sánchez and Ana Fernández-Carballido30. Sleep: cannabis and cannabinoids use Eric Murillo-Rodríguez31. Cannabis and cannabis related products and their uses in aiding sexual health of men and women Lynnette Nathalie Lyzwinski32. Symptom control in palliative care settings: The role of cannabis-based medicines Leah Sera and Maximillian Stevenson33. Cannabidiol (CBD) Use in Fragile X Spectrum DisordersDevon Johnson and Randi J. Hagerman34. Hempseed (Cannabis sativa) and ameliorative effects in hypercholesterolemia Naveen Kaushal35. Benzodiazepines and cannabis useC. Purcell36. Features of (+)-trans-cannabidiol-2-hydroxy pentyland applications to disease: a focus on usage in diabetic nephropathy E. Munoz, Matthias Winkler, Marcus Goetz and Isabel Gonzalez Mariscal37. Medical use of cannabis: applications to Tourette syndromeKirsten R. Müller-Vahl and Natalia Szejko38. Cannabinoids and their use in chronic non-cancer pain: a new narrative review Stanley Sau-Ching Wong and Chi Wai Cheung39. Endometriosis: features and potential role of medical cannabisMike Armour and Justin Sinclair40. Cannabis usage for Crohn's disease and ulcerative colitis: a narrativeJoseph Feuerstein and Rajsavi Anand41. Medical cannabis and use in migraineJessica Jiang and Alasdair M. Barr42. Cannabidiol (CBD ) and potential in medicinal use in rheumatoid arthritis Torsten Lowin43. Role of Cannabinoids in Glaucoma: Lowering Intraocular Pressure or NeuroprotectionUjendra Kumar, Sneha Singh and Rishi Somvanshi44. Medicinal potential of anandamide as a representative endocannabinoid and its effect at the cellular level in skinAdrianna Maria Piasek and Anna Sobiepanek

VI. Resources45. Medical Cannabis and ResourcesRajkumar Rajendram

　

Neurobiology, Physiology, And The Endocannabinoid System

I. Setting the scene and introductory chapters1. Distribution of the endocannabinoid system: linking signalling and developmentMichaela Dvorakova and Anna Kalinovsky2. The endocannabinoid system, immunomodulation, and LPS-induced inflammationElliot Lloyd, Nina Nguyen and Judith Hellman3. Physiology of the endocannabinoid systems: imaging and the use of positron emission tomography (PET)Claudia Poluga, Cassis Varlow, Neil Vasdev, Isabelle Boileau and Laura M. Best4. The endocannabinoid system and agingProf. Vahid Reza Askari5. The endocannabinoid system and post traumatic stress disorder (PTSD): a new narrativeLuke Ney, Kevin Crombie and Leah M. Mayo

II. Neurobiology of the endocannabinoid system6. The protective effect of the endocannabinoid system in neurotoxin induced damage to hippocampal neurons: a focus on light and electron microscopy Rita Yakovlevna Gordon, Valentina Kitchigina and Irina Mikheeva7. Endocannabinoid Signaling and excitatory and inhibitory synapsesJian Liang and Corette J. Wierenga8. The endocannabinoids and potassium channels: an updated narrative Yu-Fung Lin9. Social interactions and neural activity: linking cellular studies and endocannabinoid signalling Cheryl McCormick10. Exercise and Parkinson's disease: linking in the cannabinoid type 1 (CB1) and type 2 (CB2), and mu-opioid receptorsMarucia Chacur Sr., Caroline Cristiano Real Gregório and Karina Henrique Binda11. The endocannabinoids system and endocannabinoid receptors in sleepNasreen Akhtar12. Endocannabinoids and inhalant misuse: neuropsychological aspectsJohn Woodward13. Fatty acid amide hydrolase (FAAH) in substance use disorders: FAAH regulation and inhibition in cannabis, alcohol, nicotine, stimulant, and opioid use disordersGarth E. Terry and Greta Niemela14. Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and human soluble epoxide hydrolase (sEH) enzyme inhibitors: interlinking the endocannabinoid systemStevan Pecic and Ram Kandasamy15. WWL70: linking the hydrolyses 2-arachidonoylglycerol, endocannabinoid and eicosanoid pathways: therapeutic potential and neurological diseaseMikiei Tanaka and Yumin Zhang16. Endocannabinoid catabolic enzyme inhibitors and pain alleviation Sidney Stevens Negus and Clare Diester17. The endocannabinoid system in health and disease: features in epilepsyChristopher Martínez-Aguirre, Maria de los Angeles Nuñez-Lumbreras and Luisa Lilia Rocha18. The endocannabinoid system and autoimmune demyelination: a focus on multiple sclerosisAna Bernal-Chico, Andres Baraibar, Alvaro Moreno-Garcia, Teresa Colomer, Ester Sanchez, Carmen Utrilla, Carlos Matute and Susana Mato19. Endocannabinoid signaling and the lateral habenulaJiang-Hong Ye20. On the interplay among endocannabinoid, noradrenergic and glucocorticoid systems: evidence from aversive memory studiesMoisés Dos Santos Corrêa, Raquel Fornari, Cristina A. Stern, Leandro José Bertoglio and Lucas Gazarini

III. Receptor biology and responses 21. Adenosine A2A-cannabinoid CB1 receptor heteromers in the brain: From trans-inhibition to trans-activation Ester Aso and Francisco Ciruela22. Hippocampal CB1, CB2 receptors, the endocannabinoid system and fear memory Ana Maria Raymundi and Cristina A. Stern23. Beta-caryophyllene, the CB2 cannabinoid receptor-specific agonists and wound healing Prof. S. Koyama24. The nigrostriatal dopaminergic pathway: impact of WIN 55212-2 as a potent cannaboinoid receptor agonist Enzo Perez-Valenzuela and Jose Antonio Fuentealba Evans25. Peripheral cannabinoid receptor 1 antagonists and impact on adipocytes Morvarid Kabir26. Endocannabinoid system receptors in plasma membranes : extraction, lipid rafts and the cortex Changiz Taghibiglou and Hajar Miranzadeh Mahabadi27. Applications to wound healing: cannabinoid receptor 1 antagonism and collagen depositionInês Correia-Sa28. Role of the Transient Receptor Potential Vanilloid 1 (TRPV1), a component of the endocannabinoid system, in anxiety, depression, and cocaine addictionCarmen S. Maldonado-Vlaar and Wickensonn Norze29. Allosteric modulators of the endocannabinoid system: Org27569 and cannabinoid receptor 1 (CB1)Dai Lu30. Naturally occurring DELTA-9-tetrahydrocannabinol-derivatives and binding to CB1 and CB2 receptors: Linking in the endocannabinoid systemIrene Reyes-Resina, Rafael Rivas-Santisteban, Iu Raïch, Claudia Llinás del Torrent, Jaume Lillo, Rafael Franco and Gemma Navarro

IV. Profiles and behaviour of selective endocannabinoids31. New cannabinoid receptor type 1 and 2 agonists and applications to understanding the endocannabinoid systemManuel Faundez-Parraguez32. Fatty acid amide hydrolase, the endocannabinoid anandamide and neurological disease Filomena Fezza33. The endocannabinoid-system in the immuno-biology of dendritic cells Dipyaman Ganguly34. Palmitoylethanolamide and other anandamide congeners in neuroinflammation-based disorders: linking in the endocannabinoid system Enza Palazzo35. Endocannabinoid modulation of synaptic function and behavior in the dorsomedial hypothalamusKaren M. Crosby36. Key role of anandamide and the endocannabinoid system in the modulation of cardio-renal homeostasisProf. Virna M. Martín Gimenez and Walter Manucha37. The endocannabinoid system: Signaling and social motivationRoberta Monterazzo Cysneiros and Fernanda Ribeiro

V. Exogenous, synthetic other compounds linking in the endocannabinoid system38. Safety and toxicology of the dietary cannabinoid beta-caryophylleneProf. George Oliveira Sr., Bruna Silva, Ana Santos C. L. da Silva and Luciano Silva Lopes39. Synthetic cannabimimetics: an overview Prof. M. Kassiou

VI. Compartive studies in non neurological systems 40. Non Neurological Aspects of the Endocannabinoid System: Non Alcoholic Fatty Liver DiseaseDr. R. Ghazali41. Components of the Endocannabinoid system: Hepatic expression levels of the cannabinoid receptors and microRNAsSema Bolkent and Zeynep Mine Coskun42. Tumour growth and the endocannabinoid system: investigating CB2 agonistsJosee Guindon, Isabel Castro-Piedras, Melissa McHann and Robert Barnes43. Linking Endocannabinoid System, Palmitoylethanolamide and Sarcopenia in view of therapeutic outcomesSusanna Molinari, Eleonora Maretti, Renata Battini and Eliana Leo

VII. Resources44. Endocannabinoids and Resources Rajkumar Rajendram

Product details

  • Edition: 1
  • Latest edition
  • Published: June 24, 2023
  • Language: English

About the editors

CM

Colin R. Martin

Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.
Affiliations and expertise
Visiting Professor of Perinatal Wellbeing, Institute for Health and Wellbeing, University of Suffolk, Ipswich, UK

VP

Vinood B. Patel

Dr. Patel is a Reader at the University of Westminster. After completing his PhD at King’s College London, he continued his research experience by undertaking his post-doctoral studies in the laboratory of Professor Cunningham in the Department of Biochemistry at the Wake Forest University School of Medicine, (Winston-Salem, NC, USA). This extensive project involved investigating mechanisms of hepatic mitochondrial ribosome dysfunction in alcoholic liver disease (ALD) using biophysical and proteomic techniques. These studies have led to new avenues in determining the pathology of ALD. His teaching areas at both post-graduate and undergraduate levels include clinical biochemistry, investigative pathology and laboratory investigation.
Affiliations and expertise
Reader, University of Westminster, London, UK

VP

Victor R. Preedy

Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books.
Affiliations and expertise
Professor, Department of Clinical Biochemistry, King’s College Hospital, London, UK; Emeritus Professor, Faculty of Life Sciences and Medicine, King’s College London, UK; Visiting Professor, University of Hull, UK